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Introduction
Chronic lymphocytic leukemia (CLL) is a heterogeneous
disease with a variable clinical course and overall survival
times ranging from months to decades.1 The staging systems
developed by Rai2 and Binet3 are the standard methods of
assessing survival and treatment requirements in CLL
patients, however, they are insufficient for the identification
of patients at risk of progression, especially in the early-stages
of CLL. There is a need to investigate reliable prognostic fac-
tors for predicting stable or progressive forms of CLL that
facilitate risk-adapted treatment strategies.4 Mutational status
of immunoglobulin heavy chain variable region (IgVH) corre-
lates with clinical behavior and is a powerful prognostic fac-
tor in CLL. Unmutated IgVH patients have a reduced survival
and responsiveness to chemotherapy.5,6
However, IgVH sequencing is difficult to perform in a rou-
tine laboratory, thus, finding a surrogate for IgVH mutations
seems to be an important priority. One of the proposed mark-
ers identified through transcriptional studies is the quantifica-
tion of ZAP70 expression,7,8 but there are still problems relat-
ed to the technical validation and standardization of the flow
cytometric (FC) method used for its determination, as well as
around 20% of discordant results between ZAP70 and IgVH
mutations.9 Another prognostic marker in CLL is lipoprotein
lipase (LPL), which shows itself to be as effective as IgVH
mutational status and more reliable than ZAP70 when tested
in unpurified CLL samples.10,11
In a previous gene profiling study, we identified a limited
set of genes which were expressed differentially between
unmutated and mutated CLLs.12 Cryptochrome-1 (CRY1)
emerged as one of the genes that provides a good segregation
of samples according to IgVH mutational status, in concor-
dance with previous reports.13,14 CRY1 is one of the key com-
ponents involved in circadian clock control but its role in CLL
is still little understood. 
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Chronic lymphocytic leukemia is an adult-onset leukemia
with a heterogeneous clinical behavior. When chronic
lymphocytic leukemia cases were divided on the basis of
IgVH mutational status, widely differing clinical courses
were revealed. Since IgVH sequencing is difficult to per-
form in a routine diagnostic laboratory, finding a surrogate
for IgVH mutational status seems an important priority. In
the present study, we proposed the use of Cryptochrome-
1 as a new prognostic marker in early-stage chronic lym-
phocytic leukemia. Seventy patients (Binet stage A, with-
out treatment) were included in the study. We correlated
Cryptochrome-1 mRNA with well established prognostic
markers such as IgVH mutations, ZAP70, LPL or CD38
expression and chromosomal abnormalities. High
Cryptochrome-1 expression correlated with IgVH unmutat-
ed samples. In addition, Cryptochrome-1 was a valuable
predictor of disease progression in early-stage chronic lym-
phocytic leukemia, therefore it can be introduced in clini-
cal practice with the advantage of a simplified method of
quantification.
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The objective of this study was to evaluate the prog-
nostic significance of CRY1 expression in early-stage
CLL, and its relationship with other well established
prognostic markers in CLL. 
Design and Methods
Chronic lymphocytic leukemia patients and samples
Seventy samples from previously untreated CLL
patients (Binet stage A) were included in this study after
informed consent was obtained. Clinical diagnosis was
based on standard morphological and immunopheno-
typic criteria. Definition of progressive disease was
based on the NCI guidelines.15
Mononuclear cells (PBMC) were isolated from periph-
eral blood by Ficoll-Hypaque (Lymphoprep™) density
centrifugation. Samples were then processed for CD19+
selection, FC analysis and DNA/RNA isolation.
Analysis of IgVH somatic mutation status
DNA was prepared using a standard protocol and
IgVH gene rearrangements were performed using BIO-
MED-2 primers.16 We considered unmutated those
samples with ≥98% homology with the closest germi-
nal line.
RTqPCR assays
cDNA was synthesized from 1.5 µg of total RNA
using random hexanucleotides and SuperScriptII
(Invitrogen) following the manufacturer’s instructions.
RTqPCR assays were carried out using “Hs00172734-
m1 (CRY1), Hs00277148-m1 (ZAP70) and
Hs00173425-m1 (LPL) primers and probe sets
(TaqMan® Gene Expression Assays, Applied
Biosystems). Amplification of GUS gene was per-
formed in all cases to normalize gene expression.
Interphase fluorescence in situ hybridization (FISH)
A panel of commercially available probes (Vysis)
was used to target chromosomes 11q22.3 (ATM),
13q14 (D13S25 and D13S319), 17p13 (TP53) deletions
and trisomy 12 on blood smears according to a stan-
dard protocol. 
ZAP70 flow cytometry assay
Intracellular ZAP-70 expression was analyzed in 69
samples by FC according to Crespo et al.17 with some
modifications. We use an isotype control as negative
control. Results ≥20% were considered positive.
Statistical analysis
Significant differences between groups were
assessed by the Mann-Whitney test and considered
significant when p values <0.05. All statistical calcula-
tions were performed using the SPSS 13.0 software.
Progression free survival (PFS) was calculated from the
date of diagnosis to disease progression or last follow-
up. For more detailed information see the Online
Supplementary Appendix. 
Results and Discussion
CRY1 expression and IgVH mutational status
Out of the 70 Binet’s stage A patients tested for IgVH
mutational status, 50 were mutated in IgVH genes
(71.4%). These percentages are slightly different from
those reported in previous studies6,18,19 because in most
of them, patients with different stages of the disease
were included. 
To assess the usefulness of CRY1 expression as sur-
rogate marker for IgVH mutational status, we deter-
mined CRY1 by RTqPCR in CD19+ cell samples. The
mean ± 2 SEM relative concentration in unmutated
and mutated samples were: 0.311±0.081 and
0.034±0.023, respectively, p<0.0001 (Online Suppl-
ementary Figure S1).
The optimal predictive model based on CRY1
expression in relation to IgVH mutational status yield-
ed an area under ROC curve of 0.963. A cut-off value
that best segregates IgVH unmutated from mutated
cases for CRY1 relative concentration of 0.090 was
selected (95% sensitivity and 92% specificity). Our
data show 92.8% of concordant results between
CRY1 expression and IgVH mutational status (Online
Supplementary Table S1).
We have also analyzed CRY1 expression in 18 sam-
ples without B-cell selection. The results showed that
CRY1 was able to distinguish between IgVH unmutat-
ed and mutated samples (mean values: 0.380 and
0.051, for unmutated and mutated groups respective-
ly, p=0.007). Therefore, our results reveal that CRY1
mRNA expression can be analyzed in PBMC as well as
CD19+ selected B cells. CRY1 expression was higher in
unmutated CLLs than in mutated ones, but the rea-
sons for this differential expression are still unknown. 
CRY1 expression in relation to ZAP70, CD38 or LPL
expression and cytogenetic abnormalities
ZAP70 expression was measured by FC and RTqPCR
in leukemic B cells, CD38 was determined by FC and LPL
by RTqPCR. ROC curves were used to evaluate the per-
formance of each assay. The areas under the curves were
0.835 and 0.880 for ZAP70 measured by FC and RTqPCR
respectively, 0.963 for LPL and 0.666 for CD38. Taking
into account these results, CRY1 and LPL are the mark-
ers that better assess IgVH mutational status.
Next, we analyzed correlations between continuous
variables using Spearman’s test, and strong significance
was found for CRY1 and LPL or ZAP70 (p<0.001).
Other independent prognostic markers in CLL are
cytogenetic abnormalities. We performed FISH analysis
on 61 CLL samples. Abnormalities were seen in 54.1%
(33/61) of patients. The correlation of CRY1 expression
and the presence of the different chromosomal aberra-
tions is shown in Table 1. Remarkably, loss of 13q14,
which as a single abnormality is associated with a
favourable prognosis,20 was associated with low expres-
sion of CRY1, except in one case. Deletion of 17p13
which is associated with bad prognosis was detected in
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one case in combination with trisomy 12, this case was
IgVH unmutated, with high expression of CRY1 and pos-
itive values of CD38 and ZAP70. 
In order to compare variables, we chose a cut-off value
that best segregates IgVH unmutated from mutated cases
for each variable, therefore cases were scored as positive
(+) or negative (–) according to this criteria. Table 2 shows
concordance percentages between expression of CRY1
and ZAP70, CD38 or LPL. Both methods for ZAP70 esti-
mation displayed strong concordance with CRY1
expression, with slightly better results in the case of
RTqPCR. A better correlation was obtained between
CRY1 and LPL expression, with a concordance ratio of
90.0% whereas CD38 show the lowest percentage of
concordant results (69.8%). 
Given the strong prognostic value shown by CRY1,
ZAP70 and IgVH mutational status, we studied the corre-
lation between all of them, as well as the discordant
results. A perfect correlation was obtained with all dou-
ble-negative patients, ZAP70- by RTqPCR and CRY1-,
(n=38) showing in all cases mutated IgVH genes; where-
as, in the case of all double-positive patients, ZAP70+ by
RTqPCR and CRY1+ (n=22), 3 samples expressed mutat-
ed IgVH genes, in which one of these samples was
ZAP70– by FC as well as CD38<20% and the other 2
samples were ZAP70+ and CD38>20% by FC in both
cases. The strong correlation accounted for these mark-
ers is remarkable, but still discordant profiles represent a
14.3% of CLL patients in our study. They included 9
patients expressing ZAP70+ by RTqPCR and CRY1–, and
one patient expressing ZAP70– and CRY1+. Among these
discordant patients with ZAP70+/CRY1– profiles, 8 had
mutated IgVH gene, whereas one was unmutated (this
sample was ZAP70– by FC). On the other hand, the dis-
cordant patient with ZAP70–/CRY1+ displayed mutated
IgVH gene, but this patient had high CD38 expression.
Notably, from the 10 CRY1/ZAP70 discordant patients,
in 8 cases CRY1 was useful to assign IgVH mutational
status correctly (Online Supplementary Table S2). 
| 282 | haematologica | 2009; 94(2)
E. Jantus Lewintre et al. 
Table 1. Cryptochrome-1 gene expression in relation to cytogenetic
abnormalities.
Cytogenetic CRY1+ CRY1– Total
abnormalities (≥0.090) (<0.090) n=61
n=18 n=43
normal 10 18 28
del 13q14 1 22 23
trisomy 12 5 2 7
del 11q22.3 (ATM) 1 1 2
del 17p13 (TP53)* 1 0 1
There were 61 cases with FISH results available. *This case shows a complex
karyotype, combining del 17p13 and trisomy 12.
Table 2. Relation between CRY1 and CD38, ZAP70 or LPL expres-
sion.
Status CRY1+ CRY1– Concordance p 
(cut-off (≥0.090) (<0.090) (χ2)
value) n % n % %
ZAP70 by Positive 18 26.1 6 8.7 84.1 <0.0001
FC (≥20%)
Negative 5 7.2 40 58.0
(<20%)
ZAP70 by Positive 22 31.4 9 12.9 85.7 <0.0001
RTqPCR (≥0.1050)
Negative 1 1.4 38 54.3
(<0.1050)
LPL by Positive 21 30.0 5 7.1 90.0 <0.0001
RTqPCR (≥82.45)
Negative 2 2.9 42 60.0
(<82.45)
CD38 by Positive 12 19.0 9 14.3 69.8 0.012
FC (≥20%)
Negative 10 15.9 32 50.8
(< 20%)
CRY1 and LPL were determined by RTqPCR.CD38 was determined by FC.ZAP70
was measured by both methods: FC and RTqPCR.Cut-off values for RTqPCR were
selected using Youden index.
Figure 1. Kaplan–Meier plots. (A) PFS according to IgVH mutation-
al status. (B) PFS according to CRY1 gene expression.
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Interestingly, with IgVH mutational status as the com-
parison method, CRY1 expression showed 92.8%
agreement in terms of results, a much better perform-
ance than ZAP70 measured by FC and RTqPCR (82.6%
and 84.3% of agreement respectively) which is until
now the most used surrogate marker for IgVH muta-
tions.
We have also compared the performance of CRY1
against LPL which is one of the newest prognostic
markers proposed in CLL.10,11,13,21 The concordance
between CRY1 and LPL expression was high, with only
7 discordant results. All double-positive samples, except
2, were unmutated for IgVH. Among the discordant
results, there were 2 cases CRY1+/ LPL–, and both were
IgVH mutated, thus LPL would assign mutational status
correctly in those cases. In the case of the other 5 discor-
dant samples (CRY1-/LPL+), 4 of them were IgVH mutat-
ed, therefore CRY1 behaves as a better surrogate mark-
er than LPL in this group of samples (Online
Supplementary Table S2).
CRY1 expression and survival
We evaluated CRY1 as a new marker of disease pro-
gression in our group of early-stage CLL patients in
comparison with other prognostic markers. The median
PFS was 49.67 months (95% CI, 38.79-69.55 months) in
CLLs displaying unmutated IgVH genes whereas the
median PFS was not achieved in mutated patients,
p<0.0001 (Figure 1A). The estimated mean survival for
patients with CRY1 values ≥0.090 was 63.20 months
(95% CI, 48.17–78.23), and 139 months (95% CI,
133.12–146.43) for patients with CRY1 values below
0.090, p<0.0001 (Figure 1B). In PFS curves for ZAP70
measured by FC and RTqPCR there was a better distinc-
tion between groups in the case of RTqPCR determina-
tions (p=0.001 and p=0.054 for RTqPCR and FC respec-
tively). LPL was also a strong predictor for PFS in our
group of patients. Thus, LPL positive cases have a signif-
icantly shorter median PFS than negative cases,
p<0.0001 (Online Supplementary Figure S2). Among the
parameters studied, CRY1, LPL and IgVH mutational sta-
tus were those which better exhibited association with
PFS in early-stage CLL. 
In summary, it is well known that IgVH mutational
status is a reliable prognostic marker in CLL,5,6 but its
determination is laborious and time-consuming, It is
tempting, therefore, to search for other markers. Here,
we showed that CRY1 quantification by RTqPCR may
constitute a new prognostic marker in CLL. CRY1 is a
key component of the circadian clock. Recent epidemi-
ological studies have raised the possibility that disrup-
tion of the circadian clock may increase the risk of
developing cancer in humans and adversely affect prog-
nosis in cancer patients.22 A cyclic and significant expres-
sion of circadian clock genes in peripheral mononuclear
blood cells of healthy individuals23 and an anomalous
expression of CRY1 (among other components of the
biological clock) has been documented during chronic
and blastic phases of chronic myeloid leukemia.24 In our
study, CRY1 show a similar or better behavior than
other well established biomarkers in CLL, such as
ZAP70, CD38, LPL or cytogenetic abnormalities, and an
excellent correlation with IgVH mutational status. Our
observation, along with the easiness of CRY1 determi-
nation by RTqPCR on B lymphocytes or unselected
PBMC, indicate that CRY1 may be used as a new mark-
er of disease progression for the initial prognostic
assessment of early-stage CLL. In addition, it would be
interesting to introduce this marker in clinical trials for
its evaluation in larger cohorts of patients.
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